Sugi Predict

Sugi Predict / Compounds / Ethane

Ethane

Ethane

SCHEMBL5192964

CC.O=C=NCCCC(=O)O

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.43
▸ SLC22A6 Q4U2R8 2/20 0.43
▸ TSHR P16473 5/20 0.42
▸ NFKB1 P19838 1/20 0.42
▸ PMP22 Q01453 1/20 0.42
▸ AKR1B1 P15121 1/20 0.41
▸ GPR84 Q9NQS5 7/20 0.39
▸ PPARG P37231 7/20 0.39
▸ PPARD Q03181 7/20 0.39
▸ PPARA Q07869 7/20 0.39
▸ HDAC11 Q96DB2 5/20 0.39
▸ PTPN1 P18031 3/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ TLR2 O60603 2/20 0.39
▸ TDP1 Q9NUW8 2/20 0.39
▸ FABP4 P15090 2/20 0.39
▸ SLC22A8 Q8TCC7 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ ESR1 P03372 1/20 0.39
▸ ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3090511 0.95 — —
Hydrochloric Acid SCHEMBL9459862 0.93 LMNA (0.46) LMNASLC22A6TSHRNFKB1PMP22
SCHEMBL27455689 0.88 LMNA (0.52) LMNASLC22A6TSHRNFKB1PMP22
SCHEMBL4522248 0.86 TSHR (0.55) LMNASLC22A6TSHRNFKB1PMP22
SCHEMBL4534096 0.86 TSHR (0.55) LMNASLC22A6TSHRNFKB1PMP22
SCHEMBL4528856 0.86 TSHR (0.55) LMNASLC22A6TSHRNFKB1PMP22
SCHEMBL4535190 0.86 TSHR (0.55) LMNASLC22A6TSHRNFKB1PMP22
SCHEMBL4516537 0.86 TSHR (0.55) LMNASLC22A6TSHRNFKB1PMP22
SCHEMBL4538830 0.86 TSHR (0.55) LMNASLC22A6TSHRNFKB1PMP22
SCHEMBL4520459 0.86 TSHR (0.55) LMNASLC22A6TSHRNFKB1PMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117384100-A Carbendazim hapten and artificial antigen as well as preparation methods and application thereof 河南农业大学 2024-01-12 — — CN claimed
CN-117384100-A Carbendazim hapten and artificial antigen as well as preparation methods and application thereof 河南农业大学 2024-01-12 — — CN disclosed
EP-1812410-A2 INDINAVIR DERIVATIVES USEFUL IN IMMUNOASSAY Roche Diagnostics GmbH (DE) 2007-08-01 — — EP disclosed
US-7202092-B2 Indinavir derivatives useful in immunoassay ROCHE DIAGNOSTICS OPERATIONS, INC. (US) 2007-04-10 — — US disclosed
WO-2006050964-A2 INDINAVIR DERIVATIVES USEFUL IN IMMUNOASSAY ROCHE DIAGNOSTICS GMBH (DE) 2006-05-18 — — WO disclosed
US-20050148596-A1 Indinavir derivatives useful in immunoassay ROCHE DIAGNOSTICS OPERATIONS, INC. 2005-07-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148596-A1 Indinavir derivatives useful in immunoassay IMPDH1, DIMT1, INMT LMNA 4832/4885SLC22A6 3151/4885TSHR 1817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.